These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35613159)

  • 21. [A case of chagas infection caused by an atypical strain of Trypanosoma cruzi in a newborn infant].
    de Storni P; Bakos E; Bustamante A; Vanioff JA
    Medicina (B Aires); 1984; 44(3):287-91. PubMed ID: 6443628
    [No Abstract]   [Full Text] [Related]  

  • 22. Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.
    Jurado Medina L; Chassaing E; Ballering G; Gonzalez N; Marqué L; Liehl P; Pottel H; de Boer J; Chatelain E; Zrein M; Altcheh J
    Lancet Infect Dis; 2021 Aug; 21(8):1141-1150. PubMed ID: 33836157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
    Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
    Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi.
    Koovits PJ; Dessoy MA; Matheeussen A; Maes L; Caljon G; Mowbray CE; Kratz JM; Dias LC
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126779. PubMed ID: 31706667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New insights into pathophysiology and treatment in Chagas-Mazza disease].
    Rivarola HW; Paglini-Oliva P
    Rev Fac Cien Med Univ Nac Cordoba; 2011; 68(4):154-63. PubMed ID: 22668568
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined use of ascorbic acid and cyanocobalamin in clearance of Trypanosoma cruzi.
    Ghobadifar MA; Kalani N; Gitiforouz M
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):401-2. PubMed ID: 24857404
    [No Abstract]   [Full Text] [Related]  

  • 27.
    Mercaldi GF; Eufrásio AG; Ranzani AT; do Nascimento Faria J; Mota SGR; Fagundes M; Bruder M; Cordeiro AT
    ACS Infect Dis; 2021 Aug; 7(8):2455-2471. PubMed ID: 34279922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trypanosoma cruzi: allopurinol in the treatment of mice with experimental acute Chagas disease.
    Avila JL; Avila A
    Exp Parasitol; 1981 Apr; 51(2):204-8. PubMed ID: 6781917
    [No Abstract]   [Full Text] [Related]  

  • 29. Etiological treatment for infection by Trypanosoma cruzi.
    Amato Neto V
    Rev Inst Med Trop Sao Paulo; 1999; 41(4):211-3. PubMed ID: 10564912
    [No Abstract]   [Full Text] [Related]  

  • 30. Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition.
    Martín-Escolano R; Martín-Escolano J; Ballesteros-Garrido R; Cirauqui N; Abarca B; Rosales MJ; Sánchez-Moreno M; Ballesteros R; Marín C
    Parasitol Res; 2020 Sep; 119(9):2943-2954. PubMed ID: 32607710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural products and Chagas' disease: a review of plant compounds studied for activity against Trypanosoma cruzi.
    Izumi E; Ueda-Nakamura T; Dias Filho BP; Veiga Júnior VF; Nakamura CV
    Nat Prod Rep; 2011 Apr; 28(4):809-23. PubMed ID: 21290079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limitations of currently available Chagas disease chemotherapy.
    Murcia L; Carrilero B; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):1-3. PubMed ID: 22488534
    [No Abstract]   [Full Text] [Related]  

  • 33. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 34. Recognizing and meeting the challenge of Chagas disease in the USA.
    Bowling J; Walter EA
    Expert Rev Anti Infect Ther; 2009 Dec; 7(10):1223-34. PubMed ID: 19968514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent developments in the identification of chemotherapeutics for Chagas disease.
    Lockman JW; Hamilton AD
    Curr Med Chem; 2005; 12(8):945-59. PubMed ID: 15853707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
    Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
    Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kissing Bugs Harboring Trypanosoma cruzi, Frequently Bite Residents of the US Southwest But Do Not Cause Chagas Disease.
    Behrens-Bradley N; Smith S; Beatty NL; Love M; Ahmad N; Dorn PL; Schmidt JO; Klotz SA
    Am J Med; 2020 Jan; 133(1):108-114.e13. PubMed ID: 31295438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etiological treatment of chronic Chagas disease.
    Cançado JR
    Rev Inst Med Trop Sao Paulo; 2001; 43(3):173-81. PubMed ID: 11452329
    [No Abstract]   [Full Text] [Related]  

  • 39. Antitrypanosomal therapy for chronic Chagas' disease.
    Bestetti RB; Cardinalli-Neto A
    N Engl J Med; 2011 Sep; 365(13):1258-9; author reply 1259. PubMed ID: 21991909
    [No Abstract]   [Full Text] [Related]  

  • 40. Antitrypanosomal therapy for chronic Chagas' disease.
    Garcia-Bournissen F; Altcheh J
    N Engl J Med; 2011 Sep; 365(13):1258; author reply 1259. PubMed ID: 21991908
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.